Related Experiment Video
Updated: Jan 29, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
Published on: June 21, 2024
An Inducible BRCA1 Expression System with In Vivo Applicability Uncovers Activity of the Combination of ATR and PARP
Elsa Irving1, Alaide Morcavallo1, Jekaterina Vohhodina-Tretjakova1
1Bioscience, Oncology Targeted Discovery, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, UK.
Background:
Poly(ADP-ribose) polymerase inhibitors (PARPi) have transformed cancer therapy for patients harbouring homologous recombination repair (HRR) deficiencies, notably BRCA1/2 mutations. However, resistance to PARPi remains a clinical challenge, with restoration of BRCA1 function via hypomorphic variants representing an understudied scenario.
Methods:
Here, we engineered a doxycycline-inducible BRCA1 expression system in the BRCA1-mutant, triple-negative breast cancer cell line MDAMB436, permitting controlled analysis of functionally distinct BRCA1 hypomorphs in vitro and in vivo.
Results:
Among multiple BRCA1 variants generated-including RING, coiled-coil, and BRCT domain mutants-only overexpression of the ∆exon11 hypomorph robustly conferred resistance to olaparib and carboplatin, with drug sensitivity correlating to ∆exon11 expression levels. While ∆exon11 BRCA1 mediated HRR restoration, its efficiency was consistently lower than full-length BRCA1, as measured by RAD51 foci formation and interaction with repair partners such as PALB2. In vivo, tumours expressing Δexon11 BRCA1 exhibited only partial resistance to olaparib compared to those expressing full-length BRCA1. Importantly, the combination of olaparib and the ATR inhibitor, ceralasertib, overcame ∆exon11-mediated resistance, impairing RAD51 foci formation in ∆exon11-expressing cells.
Conclusions:
Our findings identify a dose-dependent, hypomorphic HRR restoration by ∆exon11 BRCA1, help explain the variable resistance observed in BRCA1-mutant pre-clinical models expressing this hypomorph, and propose ATR inhibition in combination with PARPi as a clinical strategy to counteract therapeutic resistance mediated by ∆exon11 BRCA1 hypomorphs.
Insights
A BRCA1 variant, ∆exon11, confers partial resistance to PARPi by restoring homologous recombination repair (HRR). Combining PARPi with ATR inhibitors overcomes this resistance, offering a new therapeutic strategy for BRCA1-mutant cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Poly(ADP-ribose) polymerase inhibitors (PARPi) are effective against homologous recombination repair (HRR) deficient cancers, particularly those with BRCA1/2 mutations.
- Therapeutic resistance to PARPi is a significant clinical challenge.
- The role of BRCA1 hypomorphic variants in PARPi resistance is not well understood.
Purpose of the Study:
- To investigate the impact of distinct BRCA1 hypomorphic variants on PARPi sensitivity.
- To elucidate the mechanism of resistance mediated by the ∆exon11 BRCA1 variant.
- To identify potential combination therapies to overcome PARPi resistance.
Main Methods:
- Engineered a doxycycline-inducible BRCA1 expression system in a BRCA1-mutant triple-negative breast cancer cell line (MDAMB436).
- Assessed the in vitro and in vivo effects of various BRCA1 variants, including ∆exon11, on drug sensitivity and HRR.
- Measured HRR restoration by RAD51 foci formation and interaction with repair partners like PALB2.
- Evaluated the efficacy of combining olaparib with the ATR inhibitor ceralasertib.
Main Results:
- Overexpression of the ∆exon11 BRCA1 hypomorph conferred resistance to olaparib and carboplatin in a dose-dependent manner.
- ∆exon11 BRCA1 partially restored HRR, but less efficiently than full-length BRCA1, evidenced by reduced RAD51 foci and PALB2 interaction.
- Tumors expressing ∆exon11 BRCA1 showed only partial resistance to olaparib in vivo.
- The combination of olaparib and ceralasertib effectively overcame ∆exon11-mediated resistance and impaired RAD51 foci formation.
Conclusions:
- The ∆exon11 BRCA1 hypomorph mediates a dose-dependent, partial restoration of HRR, explaining variable PARPi resistance in preclinical models.
- ATR inhibition combined with PARPi represents a promising clinical strategy to counteract resistance driven by ∆exon11 BRCA1 hypomorphs.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Gene Therapy
Induced Electric Fields: Applications
Attenuated Total Reflectance (ATR) Infrared Spectroscopy: Overview
The ATR process begins by directing a beam...
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

